Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiological Study on Community Acquired Pneumonia (CAPNETZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02139163
Recruitment Status : Recruiting
First Posted : May 15, 2014
Last Update Posted : July 31, 2020
Sponsor:
Information provided by (Responsible Party):
Hannover Medical School

Brief Summary:
Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia.

Condition or disease Intervention/treatment
Community Acquired Pneumonia Other: Cohort Study

Detailed Description:
Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia. The aim of the study CAPNETZ is to improve diagnosis, treatment and patient care.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 10150 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Epidemiological Study on Community Acquired Pneumonia
Study Start Date : October 2002
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Group/Cohort Intervention/treatment
patients with pneumonia Other: Cohort Study



Primary Outcome Measures :
  1. diagnosis [ Time Frame: 2 weeks ]

    Assessment of diagnosis:

    Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.


  2. therapy [ Time Frame: 2 weeks ]

    Assessment of therapy:

    Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.


  3. hospitalization [ Time Frame: 2 weeks ]

    Assessment of hospitalization:

    Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with pneumonia
Criteria

Inclusion Criteria:

  • age ≥ 18
  • infiltrate on chest X-ray
  • further Inclusion criteria: cough or production of purulent sputum or pathologic lung auscultation (crackles) or fever

Exclusion Criteria:

  • hospital inpatient treatment within the last 28 days
  • Immune suppressed patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02139163


Contacts
Layout table for location contacts
Contact: Tobias Welte, Prof. +49-511-532-5927 office@capnetz.de

Locations
Layout table for location information
Germany
CAPNETZ FOUNDATION Hannover Medical School (MHH) Recruiting
Hannover, Niedersachsen, Germany, 30625
Contact: Abrahamczik    +49-(0)511-532-5927    Abrahamczik.margarete@mh-hannover.de   
Contact: Kroener    +49-(0)511-532-4447    Kroener.Waldemar@mh-hannover.de   
Principal Investigator: Tobias Welte, Prof.         
Hannover Medical School Recruiting
Hannover, Niedersachsen, Germany, 30625
Contact: Tobias Welte, Prof.    +49-511-532-5927    office@capnetz.de   
Sponsors and Collaborators
Hannover Medical School
Investigators
Layout table for investigator information
Study Chair: Tobias Welte, Prof. Dr. Hannover Medical School
Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Hannover Medical School
ClinicalTrials.gov Identifier: NCT02139163    
Other Study ID Numbers: U1111-1147-8393
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: July 31, 2020
Last Verified: July 2020
Keywords provided by Hannover Medical School:
Community acquired pneumonia
CAP
CAPNETZ
age ≥18
infiltrate on chest X-ray
cough or production of purulent sputum
pathologic lung auscultation
fever
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections